Alpheus Medical, Inc. has presented exploratory clinical findings suggesting that changes in blood lactate dehydrogenase levels over time could provide additional information about disease activity in patients with recurrent glioblastoma. Announced on October 27, 2026, the findings were drawn from 15 patients treated with the company’s investigational Porphyrin Metabolite Activation therapy and presented at the European Society for Medical Oncology Congress 2026 in Madrid.
The analysis focused on serial lactate dehydrogenase measurements rather than individual test results. Alpheus Medical reported that sustained increases in the enzyme were associated with clinical deterioration, while patients without evidence of clinical progression generally displayed stable or declining levels. The observations raise the possibility of using an accessible blood test to complement magnetic resonance imaging when assessing glioblastoma, although the evidence remains preliminary.
The findings do not establish lactate dehydrogenase as a validated diagnostic or monitoring biomarker for glioblastoma. The analysis involved a small, selected population, and the company has not demonstrated that LDH-guided clinical decisions improve patient outcomes. Prospective evaluation will be necessary to determine whether the observed patterns are reliable, sufficiently specific and useful beyond existing clinical and imaging assessments.
What did Alpheus Medical’s ESMO 2026 study reveal about serial LDH measurements in recurrent glioblastoma?
The exploratory analysis was presented in poster 4289P at the European Society for Medical Oncology Congress 2026. It examined 15 patients with MGMT-unmethylated recurrent glioblastoma who had received the investigational Porphyrin Metabolite Activation treatment, known as PoMA. Investigators evaluated how LDH measurements changed during treatment and whether those changes corresponded with clinical assessments and imaging findings.
According to Alpheus Medical, patients without evidence of clinical disease progression generally maintained stable or declining LDH concentrations. By contrast, all patients classified as experiencing clinical deterioration showed sustained increases during treatment. This relationship suggests that changes in LDH over several measurements may provide more information than a single result interpreted without reference to its trajectory.
The findings were particularly interesting in patients whose imaging suggested possible disease progression. Alpheus Medical reported that these patients generally maintained stable LDH measurements, creating a difference between radiographic appearances and the blood biomarker pattern. The company believes this divergence warrants investigation because treatment-related imaging changes can resemble tumour growth, making some glioblastoma assessments difficult to interpret.
The analysis also explored whether specific patterns of LDH increase were more informative than isolated fluctuations. Consecutive elevations or a large initial increase appeared more closely associated with disease status than relatively small individual changes. However, the announcement did not provide sufficient diagnostic performance data to establish validated sensitivity, specificity or clinically actionable thresholds.
Why is distinguishing true glioblastoma progression from treatment-related MRI changes so difficult?
Glioblastoma is an aggressive primary brain malignancy characterised by infiltrative growth and a high likelihood of recurrence despite treatment. Disease monitoring relies heavily on magnetic resonance imaging, neurological assessment and the patient’s overall clinical condition. However, MRI does not always distinguish active tumour growth from changes caused by previous treatment.
One important complication is pseudoprogression, where treatment-related inflammation or injury produces imaging abnormalities that resemble worsening cancer. Such changes can occur following radiotherapy and chemotherapy, particularly during the early post-treatment period. An inaccurate interpretation may create uncertainty over whether the existing treatment should continue or whether the patient has developed progressive disease.
The Response Assessment in Neuro-Oncology criteria, including the RANO 2.0 framework, recognise the importance of confirming progression in selected clinical circumstances. Imaging changes must be interpreted alongside treatment timing, clinical status and other relevant information. Additional imaging or follow-up may be necessary when the findings are equivocal.
This creates a potential role for complementary biomarkers that reflect biological changes associated with tumour activity. A reliable blood-based measurement might help clinicians interpret ambiguous cases, particularly if it provides information independent of structural imaging. However, a useful biomarker must distinguish relevant tumour behaviour from treatment toxicity, infection, systemic illness and other causes of abnormal blood results.
How could serial lactate dehydrogenase testing contribute to glioblastoma monitoring without replacing MRI?
Lactate dehydrogenase is an enzyme involved in cellular energy metabolism and is present in multiple tissues throughout the body. Blood LDH concentrations can increase when cells are damaged or when particular disease processes alter tissue metabolism. The test is already familiar to clinical laboratories, making it technically more accessible than many experimental molecular biomarker assays.
Its principal limitation is biological non-specificity. Elevated LDH can occur in several conditions involving the liver, blood, muscles and other tissues, while sample haemolysis can also affect results. Consequently, an increase cannot independently establish that a brain tumour is progressing or identify the anatomical source of the abnormality.
The Alpheus Medical analysis proposes a different interpretation strategy by focusing on the direction and persistence of LDH changes. A series of measurements may reveal patterns that are obscured when clinicians examine isolated values. Nevertheless, observing a trend does not establish its cause, and the same biological confounders can influence repeated measurements.
Any future clinical application would likely require LDH to be interpreted alongside imaging, neurological examination and other patient-specific findings. Serial testing might eventually help identify situations requiring additional assessment, but it cannot currently determine whether suspected progression is genuine. Alpheus Medical has appropriately positioned the findings as a potential complementary biomarker rather than a replacement for established glioblastoma monitoring.
How does the LDH biomarker research connect with Alpheus Medical’s investigational PoMA treatment programme?
The exploratory biomarker findings emerged from patients receiving Alpheus Medical’s investigational Porphyrin Metabolite Activation therapy. PoMA combines 5-aminolevulinic acid with low-intensity defocused ultrasound in an effort to exploit biological differences between tumour and normal tissue. The treatment is designed to activate protoporphyrin IX, a compound that can accumulate preferentially in tumour cells following administration of 5-aminolevulinic acid.
The intended therapeutic mechanism involves exposing sensitised tissue to ultrasound energy to produce a local biological effect. Alpheus Medical is developing this strategy as a non-invasive treatment approach for glioblastoma, including infiltrative disease that is difficult to address through conventional local interventions. However, the mechanism remains under clinical investigation, and the biomarker findings do not independently establish treatment effectiveness.
PoMA has also progressed beyond the original first-in-human investigation. Alpheus Medical is conducting a randomised Phase 2b study in newly diagnosed glioblastoma, registered as NCT07225621, alongside a separate investigation in newly diagnosed butterfly glioblastoma, registered as NCT07862647. These studies address different clinical questions from the retrospective interpretation of LDH measurements in previously treated recurrent disease.
The Phase 2b programme evaluates investigational sonodynamic treatment in combination with standard glioblastoma management. Its controlled design should help establish whether the treatment contributes measurable clinical benefit beyond the comparator regimen. The LDH research could become relevant to future study monitoring, although its incorporation into prospective endpoints or treatment decisions would require a defined validation strategy.
What statistical and clinical limitations prevent the 15-patient LDH findings from becoming a validated biomarker?
The most immediate limitation is the small sample size. An analysis involving 15 patients can generate a useful biological hypothesis, but it provides limited precision when estimating diagnostic performance or determining how consistently a biomarker behaves. A few additional or differently classified cases could materially change the apparent relationship between LDH changes and disease status.
The study population was also clinically selected. Participants had MGMT-unmethylated recurrent glioblastoma and were receiving an investigational treatment, meaning the results may not apply directly to newly diagnosed patients, different molecular subgroups or individuals receiving other therapies. Treatment-specific biological effects could also influence LDH measurements independently of tumour progression.
Another important question concerns how clinical deterioration was determined. If LDH patterns are compared primarily with investigator-assessed clinical status, researchers must establish how well those assessments distinguish tumour activity from other causes of worsening health. Independent or blinded adjudication and predefined diagnostic criteria would strengthen confidence in future findings.
The timing and frequency of blood sampling are equally important. Biomarker trajectories can be affected by laboratory variability, intercurrent illness, medication exposure and the interval between measurements. Any prospective study would need to specify how sustained increases are defined and assess whether those thresholds work consistently across patients.
A validated biomarker would also need to demonstrate incremental clinical value. It is not enough to show that an abnormal result often occurs in patients who are already visibly deteriorating. The more consequential question is whether LDH provides accurate information earlier, clarifies genuinely ambiguous imaging findings or improves assessment beyond what clinicians can already determine.
Could blood-based LDH monitoring offer a practical advantage over more specialised glioblastoma biomarkers?
Blood-based monitoring is an active area of neuro-oncology research, including approaches that investigate circulating tumour DNA, extracellular vesicles, proteins and metabolic markers. Many of these methods face technical challenges because the brain tumour environment and blood-brain barrier can limit the amount of tumour-derived material detectable in peripheral blood. Some assays also require specialised laboratory infrastructure that may constrain routine deployment.
LDH has a practical advantage because measurement is already widely available through conventional clinical chemistry laboratories. If a reproducible relationship with glioblastoma progression were established, implementation could be less technically demanding than introducing a new molecular diagnostic platform. However, the test’s familiarity does not overcome its lack of tumour specificity.
Specialised molecular biomarkers and LDH also address somewhat different biological questions. Tumour-derived genetic material may potentially provide disease-specific information, whereas LDH reflects broader metabolic or tissue-related processes. The clinical usefulness of each approach depends on whether its measurements correlate reliably with meaningful disease outcomes.
This distinction limits the case for treating LDH as a direct competitor to emerging molecular technologies. Its more plausible role would be as one component of a combined monitoring strategy, provided validation demonstrates additional value. Cost, accessibility and laboratory familiarity would only become commercially important after satisfactory clinical performance had been established.
What would prospective validation need to demonstrate before clinicians could rely on LDH kinetics in glioblastoma?
Alpheus Medical has indicated that it plans to prospectively evaluate the observations in a larger patient population. Such research would need to define the timing of blood collection, laboratory methods, thresholds for meaningful change and the clinical reference standard against which results are assessed. Establishing these elements before patient outcomes are known would reduce the risk of identifying patterns that perform well only in the original dataset.
Prospective evaluation should also include patients with different clinical trajectories and potential confounding conditions. Researchers would need to determine whether sustained LDH increases distinguish genuine disease progression from infection, treatment-related tissue injury or other systemic causes. The ability to identify patients with stable disease accurately would be as important as recognising those who deteriorate.
A meaningful study could examine whether LDH trajectories provide useful information before changes become evident on MRI. It could also evaluate cases in which imaging and clinical symptoms are discordant, rather than relying mainly on straightforward examples of progression. Those are the circumstances in which an additional biomarker might offer the greatest clinical value.
External validation would represent another important development requirement. Results should ideally be reproduced across different treatment centres, laboratory environments and patient populations. Consistency across these settings would provide stronger evidence that serial LDH monitoring reflects a generalisable biological relationship rather than characteristics specific to one early clinical cohort.
For Alpheus Medical, the biomarker programme could ultimately support more informative evaluation of PoMA and perhaps generate insights relevant to other glioblastoma treatments. That broader opportunity remains hypothetical because the current findings were generated in a small exploratory population. The immediate scientific priority is to demonstrate that LDH trajectories add reliable information to existing assessments without creating misleading signals.
The ESMO 2026 presentation therefore establishes a research direction rather than a new clinical monitoring standard. Alpheus Medical has identified an association that may help address a persistent problem in glioblastoma care, but its usefulness will depend on prospective diagnostic performance and clinical validation. Until those requirements are met, serial LDH kinetics should be regarded as an investigational complement to imaging, not an established measure of glioblastoma progression.
